Jefferies Financial Group Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) had its price objective reduced by investment analysts at Jefferies Financial Group from $7.00 to $3.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Financial Group's price objective points to a potential upside of 194.12% from the stock's current price.

Several other research analysts also recently commented on SGMO. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, December 19th. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Wells Fargo & Company reduced their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a research note on Tuesday. Barclays increased their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Finally, Truist Financial upgraded shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 price target for the company in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $5.50.

Sangamo Therapeutics Stock Down 56.4 %

SGMO traded down $1.32 during trading hours on Tuesday, hitting $1.02. The stock had a trading volume of 44,415,211 shares, compared to its average volume of 7,095,709. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The company's fifty day simple moving average is $2.16 and its 200 day simple moving average is $1.22. The stock has a market cap of $212.82 million, a PE ratio of -1.36 and a beta of 1.15.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter last year, the company earned ($0.34) earnings per share. As a group, equities analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in Sangamo Therapeutics in the second quarter worth $67,000. Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 6,740 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics in the second quarter valued at $89,000. XTX Topco Ltd increased its position in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 64,981 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 38,850 shares in the last quarter. Institutional investors own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.